Povetacicept by Alpine Immune Sciences for Systemic Lupus Erythematosus: Likelihood of Approval

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Povetacicept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Povetacicept overview

Povetacicept is under development for the treatment of systemic lupus erythematosus, glomerulonephritis, Sjogren’s syndrome, IgA nephropathy (Berger”s Disease), lupus nephritis, immune thrombocytopenia, acquired (autoimmune) hemolytic anemia, pemphigus foliaceus, pemphigus vulgaris and bullous pemphigoid. It is administered through intravenous and subcutaneous route. The drug candidate is an engineered B-cell modulator. It acts by targeting BAFF and APRIL. 

Alpine Immune Sciences overview

Alpine Immune Sciences (Alpine), formerly Nivalis Therapeutics Inc, is a pharmaceutical company that focuses on discovering and developing innovative, protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. It provides ALPN-101 and ALPN-303 for the treatment of based immunotherapies and immune synapses to treat cancer and autoimmune and inflammatory diseases. Nivalis Therapeutics’ ALPN-101’s potential for the treatment of inflammatory diseases. The company offers a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Nivalis Therapeutics is headquartered in Seattle, Washington, the US.

For a complete picture of Povetacicept’s drug-specific PTSR and LoA scores, buy the report here.